Policymakers respond to a crisis and every crisis has to have a villain. Unfortunately, today pharma is the villain.
The consultancy includes Double Helix, which was acquired by McCann in 2012.
Some U.S. hospitals still haven't received Valeant discounts; U.N. General Assembly will discuss antibiotic resistance; AstraZeneca diabetes drugs lowered blood sugar in study
Mylan CEO to appear before House committee about EpiPen pricing; job-related health premiums rise; GSK's experimental shingles vaccine shows 90% effectiveness
BIO launches ad campaign defending drugmakers; GSK's experimental COPD drug reduces flare-ups in patients; NY attorney general to investigate Mylan
CEO Brent Saunders also said the drugmaker will not increase the price of drugs nearing patent expiration.
In 2011 the drugmaker spent $9.4 million on branded ads for the EpiPen. By 2015, branded ad spending hit $43 million.
Mylan to launch generic EpiPen; the majority of NCCN guideline writers report conflicts of interest; Sanofi reports new trial data for Praluent
Sarah Jessica Parker cuts ties with Mylan over pricing controversy; lung-cancer physicians turn to Keytruda; Merck KGaA diversifies its business
Mylan offers additional copay assistance for EpiPen amid criticism; fewer doctors are seeing reps; two Copaxone patents are invalidated
Retzlaff files a complaint against Turing; Pfizer to buy antibiotics from AstraZeneca; Mylan's marketing for EpiPen faces criticism
The implementation of a broad outcomes-based pricing scheme is a wildly, almost gratuitously complicated project.
England's NHS delays hep-C coverage due to pricing; Google reports 21% revenue growth; U.S. and U.K. announce partnership for antibiotic development
The FDA approves generic versions of AstraZeneca's Crestor; Biogen CEO steps down; drugmakers race to develop smart inhalers
EpiPen price hikes led to syringe use; states with medical marijuana laws have drops in drug spending; Pfizer and Merck KGaA start ovarian cancer trial
Gilead CEO talks drug pricing; multiple-sclerosis drugmakers study the overall cost of care; Biden launches national cancer database
Researchers question cost of multiple-myeloma combo; drugmakers say CAR-T therapies will soon be approved; the FDA approves Allergan's hypertension drug
WHO finds poor countries are paying too much for HCV drugs; Gilead faces a lawsuit over an HIV drug; BioMarin to stop developing Duchenne treatment
Valeant has not delivered promised price breaks on heart drugs; AstraZeneca drug receives orphan status; Allergan promotes Meury and Stewart
Rising healthcare costs, coupled with high-profile stories of price gouging at some small pharmaceutical companies, have left consumers feeling ripped off
Total medicine spending surged to $424.8 billion in 2015, representing an increase of 12.2%. Here's why that growth figure is closer to 2.9%.
Pearson expected to say price hikes were too aggressive; Collegium's painkiller receives full FDA approval; most hospitals stop advertising infant formula
When pharmaceutical companies are needed, we're Jonas Salks; when we ask to be paid, we're Martin Shkrelis.
Government identifies barriers to eliminating hepatitis C; Pearson agrees to congressional deposition; CMS reportedly plans to revoke Theranos license
California bill would require price disclosures; AbbVie's and Genentech's blood-cancer drug is approved; FDA expands metformin use
The drugmaker instead suggested using an economic model it developed.
GSK won't patent drugs sold in low-income countries; experimental dermatitis therapy met Phase III endpoints; the FDA issues biosimilar labeling guidance
The American College of Physicians questioned the role direct-to-consumer advertising plays in contributing to prescription drug costs.
Pearson to be replaced at Valeant; Pfizer's Xeljanz meets Phase III goals; Harvard partners with Merck on leukemia drug development
OptumRx partners with Walgreens Boots Alliance; Turing's former lawyer said Daraprim price hike was unjustified; the White House names moonshot leader
- McCann Health forms new global consultancy
- Alexion uses superheroes, social media to raise rare-disease awareness
- Five things for pharma marketers to know: Tuesday, September 20, 2016
- Five things for pharma marketers to know: Wednesday, September 21, 2016
- Five things for pharma marketers to know: Monday, September 19, 2016
- Merck educates doctors about biosimilars, long before it will sell one in the U.S.
- 4 trends with the potential to change behavior in the patient journey
- When it comes to professional ads, print makes its comeback
- 2016 Pharma Report: All the data in one place
- What do physicians think about biosimilars?
- The FDA approves Amgen's biosimilar version of Humira
- Five things for pharma marketers to know: Friday, September 23, 2016
- Five things for pharma marketers to know: Thursday, September 22, 2016
- Drug Pricing Will Be a Key Issue, Whether Clinton or Trump Win the Election
- The Michael J. Fox Foundation uses Facebook to recruit Ashkenazi Jews for Parkinson's study